The Genetics of the Amyloidoses
10.1146/annurev.med.51.1.543
Crossref journal-article
Annual Reviews
Annual Review of Medicine (22)
Abstract

▪ Abstract  The amyloidoses are diseases in which abnormalities in the secondary structure of precursor proteins result in decreased solubility under physiologic conditions, with subsequent organ compromise. A total of 18 proteins have been definitively identified as amyloid precursors associated with human disease. Mutations in the genes that encode some of these proteins produce autosomal dominant disease in mid to late adult life. Until recently, the late onset has obscured the familial nature of some of the disorders. This is especially true in the apparently sporadic diseaseproducing deposits found even later in life. In many instances, these deposits are derived from precursors encoded by wild-type genes (perhaps influenced by alleles that are polymorphic in the normal population); in other cases, they represent autosomal dominant disease with age-dependent penetrance. The genetic aspects of amyloid diseases produced by the deposition of four different proteins have been investigated in detail and provide insights into the particular diseases and amyloidogenesis in general.

Bibliography

Buxbaum, J. N., & Tagoe, C. E. (2000). The Genetics of the Amyloidoses. Annual Review of Medicine, 51(1), 543–569.

Authors 2
  1. Joel N. Buxbaum (first)
  2. Clement E. Tagoe (additional)
References 138 Referenced 136
  1. Chiti F, Webster P, Taddei N, et al. 1999. Designing conditions forin vitroformation of amyloid protofilaments and fibrils.Proc. Natl. Acad. Sci.USA96:3590–94 (10.1073/pnas.96.7.3590)
  2. 10.1073/pnas.90.6.2375
  3. 10.1016/S0021-9258(19)42128-5 / J. Biol. Chem. (1974)
  4. Blake CCF, Geisow MJ, Oatley SJ. 1978. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8A.J. Mol. Biol.121:339–56 (10.1016/0022-2836(78)90368-6)
  5. Monaco HL, Rizzi M, Coda A. 1995. Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein.Science268:1039–41 (10.1126/science.7754382)
  6. {'key': 'b6', 'first-page': '411', 'volume': '2', 'year': '1984', 'journal-title': 'Mol. Biol. Med.'} / Mol. Biol. Med. (1984)
  7. 10.1016/0006-291X(85)91956-4
  8. 10.1093/brain/75.3.408
  9. {'key': 'b9', 'first-page': '1', 'volume': '590', 'year': '1976', 'journal-title': 'Acta Med. Scand. Suppl.'} / Acta Med. Scand. Suppl. (1976)
  10. Sakoda S, Suzuki T, Higa S, et al. 1983. Genetic studies of familial amyloid polyneuropathy in the Arao district of Japan: 1. The genealogical survey.Clin. Genet.24:334–38
  11. 10.7326/0003-4819-86-4-419
  12. Saraiva MJM, Birken S, Costa PP, Goodman DS. 1984. Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type: definition of molecular abnormality in transthyretin (prealbumin).J. Clin. Invest.74:104–19 (10.1172/JCI111390)
  13. Tawara S, Nakazato M, Kangawa K, et al. 1983. Identification of amyloid prealbumin variant in familial amyloidotic polyneuropathy (Japanese type).Biochem. Biophys. Res. Commun.116:880– 88 (10.1016/S0006-291X(83)80224-1)
  14. 10.1073/pnas.81.3.694
  15. Jacobson DR, Santiago-Schwarz F, Buxbaum JN. 1988. Restriction fragment analysis confirms the position 33 mutation in transthyretin from an Israeli patient (SKO) with familial amyloidotic polyneuropathy.Biochem. Biophys. Res. Commun.153:198–202 (10.1016/S0006-291X(88)81208-7)
  16. 10.1172/JCI113293
  17. 10.1016/0888-7543(89)90020-7
  18. 1999.Proc. Int. Symp. Fam. Amyloidotic Polyneuropathy and Other Transthyretin Relat. Disord., 4th, Int. Workshop Liver Transplant. Fam. Amyloid Polyneuropathy, 3rd,June 3–5,Umeå, Sweden
  19. {'key': 'b19', 'first-page': '308', 'volume': '95', 'year': '1995', 'journal-title': 'Hum. Genet.'} / Hum. Genet. (1995)
  20. Kelly JW, Lansbury PT Jr. 1994. A chemical approach to elucidate the mechanism of transthyretin and beta-protein amyloid fibril formation.Amyloid:Int.J. Exp. Clin. Invest.1:186–205 (10.3109/13506129409148451)
  21. Thylen C, Wahlqvist J, Haettner E, et al. 1993. Modifications of transthyretin in amyloid fibrils: analysis of amyloid from homozygous and heterozygous individuals with the Met30 mutation.EMBO J.12:743–48 (10.1002/j.1460-2075.1993.tb05708.x)
  22. McCutchen SL, Kelly J. 1993. Intermolecular disulfide linkages are not required for transthyretin amyloid fibril formationin vitro.Biochem. Biophys. Res. Commun.197:415–21 (10.1006/bbrc.1993.2495)
  23. McCutchen SL, Lai Z, Miroy GJ, et al. 1995. Comparison of lethal and nonlethal transthyretin variants and their relationship to disease.Biochemistry34:13527– 36 (10.1021/bi00041a032)
  24. Coelho T, Sousa A, Lourenco E, Ramalheira J. 1994. A study of 159 Portuguese patients with familial amyloidotic polyneuropathy (FAP) whose parents were both unaffected.J. Med. Genet.31:293– 99 (10.1136/jmg.31.4.293)
  25. Sousa A, Coelho T, Lobato L, Sequeiros J. 1999. Anticipation of age-at-onset in Portuguese patients with familial amyloid polyneuropathy-type I (FAPMet30). InAmyloidosis,ed. MA Gertz, RA Kyle. New York/London: Parthenon. In press
  26. 10.1007/s004390050991
  27. Sousa A, Coelho T, Sequeiros J. 1990. Parental transmission and age-of-onset in familial amyloidotic polyneuropathy (Portuguese type). InAmyloid and Amyloidosis,ed. JB Navtig, Ø Førre, G Husby, et al, pp. 691–93. Dordrecht, Netherlands/Norwell, MA: Kluwer (10.1007/978-94-011-3284-8_170)
  28. Ikegawa S, Yi S, Araki S, et al. 1990. Reevaluation of 134 patients with familial amyloidotic polyneuropathy (FAP) type I in Japan, Kumamoto focus. InAmyloid and Amyloidosis,ed. JB Navtig, Ø Førre, G Husby, et al, pp. 675–78. Dordrecht, Netherlands/Norwell, MA: Kluwer (10.1007/978-94-011-3284-8_166)
  29. 10.1111/j.1399-0004.1988.tb02887.x
  30. 10.1007/BF00288262
  31. Reilly MM, Adams D, Davis MB, et al. 1995. Haplotype analysis of French, British and other European patients with familial amyloid polyneuropathy (Met 30 and Tyr 77).J. Neurol.242:664–68 (10.1007/BF00866917)
  32. Ikeda S, Takei Y, Nakazato M, et al. 1999. Geographic distribution of familial amyloid polyneuropathy (FAP) in Japan. Proc. Int. Symp. Fam. Amyloidotic Polyneuropathy and Other Transthyretin Relat. Disord., 4th, Umeå, Sweden,P38:62
  33. Sousa A, Andersson R, Drugge U, et al. 1993. Familial amyloidotic polyneuropathy in Sweden: geographical distribution, age of onset, and prevalence.Hum. Hered.43:288–94 (10.1159/000154146)
  34. Holmgren G, Costa PM, Andersson C, et al. 1994. Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate.J. Med. Genet.31:351–54 (10.1136/jmg.31.5.351)
  35. Holmgren G, Ando Y, Wikström L, et al. 1997. Discordant symptoms in monozygotic twins with familial amyloidotic polyneuropathy (FAP)(TTR Met 30).Amyloid: Int. J. Exp. Clin. Invest.4:178– 80 (10.3109/13506129709014382)
  36. Soyka J. 1876. Ueber amyloide degeneration.Prag. Med. Wochenschr.9:165– 71
  37. {'key': 'b37', 'first-page': '362', 'volume': '44', 'year': '1908', 'journal-title': 'Beitr. Pathol. Anat.'} / Beitr. Pathol. Anat. (1908)
  38. 10.1073/pnas.87.7.2843
  39. Gorevic PD, Prelli FC, Wright J, et al. 1989. Systemic senile amyloidosis. Identification of a new prealbumin (transthyretin) variant in cardiac tissue: immunologic and biochemical similarity to one form of familial amyloidotic polyneuropathy.J. Clin. Invest.83:836–43 (10.1172/JCI113966)
  40. Jacobson DR, Gorevic PD, Buxbaum JN. 1990. A homozygous transthyretin variant associated with senile systemic amyloidosis: evidence for a late-onset disease of genetic etiology.Am. J. Hum. Genet.47:127–36
  41. Nichols WC, Liepnieks JJ, Snyder EL, Benson MD. 1991. Senile cardiac amyloidosis associated with homozygosity for a transthyretin variant (Ile-122).J. Lab. Clin. Med.117:175–80
  42. Saraiva MJM, Sherman W, Marboe C, et al. 1990. Cardiac amyloidosis: report of a patient heterozygous for the transthyretin-isoleucine 122 variant.Scand. J. Immunol.32:341–46 (10.1111/j.1365-3083.1990.tb02928.x)
  43. Snyder EC, Nichols WC, Liepnicks JJ, Benson MD. 1991. Direct evidence for hereditary nature of senile cardiac (systemic) amyloidosis.Am. J. Hum. Genet.45:A220 (Abstr.)
  44. 10.1007/s004390050199
  45. Booth DR, Gillmore JD, Persey MR, et al. 1999. TTR mutations in patients with senile cardiac amyloidosis. InAmyloidosis,ed. MA Gertz, RA Kyle, pp. 554– 55. New York, London: Parthenon
  46. Jacobson DR, Pastore RD, Yaghoubian R, et al. 1997. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans.N. Engl. J. Med.336:466–73 (10.1056/NEJM199702133360703)
  47. {'key': 'b47', 'first-page': '1497', 'volume': '150', 'year': '1997', 'journal-title': 'Am. J. Pathol.'} / Am. J. Pathol. (1997)
  48. Yamamura K. 1999. Development of mouse models for determination of factors involved in amyloidogenesis.Proc. Int. Symp. Fam. Amyloidotic Polyneuropathy Other Transthyretin Relat. Disord., 4th, Umeå, Sweden,S2:37
  49. Teng M, Yin J, Vidal R, et al. 1998. Age and sex-dependent amyloid fibril formation in mice transgenic for wild type human transthyretin.J. Invest. Med.46:192A (Abstr.)
  50. Buxbaum JN. 1997. The amyloidoses. InRheumatology,ed. JH Klippel, PA Dieppe, pp. 27.1–10. London: MosbyWolfe
  51. Sipe JD 1994. Amyloidosis.Crit. Rev. Clin. Lab. Sci.31:325–54 (10.3109/10408369409084679)
  52. Shiroo M, Kawahara E, Nakanishi I, Migita S. 1988. SAA2 deposition in the spleen of the mouse. InAmyloid and Amyloidosis,ed. T Isobe, S Araki, F Uchino, et al., pp. 63–68. London/New York: Plenum
  53. 10.1084/jem.148.4.1020
  54. Nomenclature Committee of the International Society of Amyloidosis. 1999. Revised nomenclature for serum amyloid A (SAA).Amyloid: Int. J. Exp. Clin. Invest.6:67–70 (10.3109/13506129908993291)
  55. Liepnieks JJ, Kluve-Beckerman B, Benson MD. 1995. Characterization of amyloid A protein in human secondary amyloidosis: the predominant deposition of serum amyloid A1.Biochim. Biophys. Acta1270:81–86 (10.1016/0925-4439(94)00076-3)
  56. Booth DR, Booth SE, Gillmore JD, et al. 1998. SAA1 alleles as risk factors in reactive systemic AA amyloidosis.Amyloid: Int. J. Exp. Clin. Invest.5:262–65 (10.3109/13506129809007299)
  57. Faulkes DJ, Woo P. 1997. Do alleles at the serum amyloid A locus influence susceptibility to reactive amyloidosis in systemic onset juvenile chronic arthritis?Amyloid: Int. J. Exp. Clin. Invest.4:75– 79 (10.3109/13506129708995274)
  58. Yamada T, Okuda Y, Itoh Y. 1998. The frequency of serum amyloid A2 alleles in the Japanese population.Amyloid: Int. J. Exp. Clin. Invest.5:208–11 (10.3109/13506129809003847)
  59. 10.1097/00005792-199807000-00005
  60. 10.1056/NEJM198604173141601
  61. 10.1056/NEJM197410312911803
  62. 10.1038/ng0997-25
  63. 10.1016/S0092-8674(00)80539-5
  64. Livneh A, Langevitz P, Shinar Y, et al. 1999. MEFV mutation analysis in patients suffering from amyloidosis of familial Mediterranean fever.Amyloid: Int. J. Exp. Clin. Invest.6:1–6 (10.3109/13506129908993281)
  65. Kindy MS, deBeer FC, Markesbery WR, et al. 1995. Apolipoprotein E genotypes in AA and AL amyloidoses.Amyloid: Int. J. Exp. Clin. Invest.2:159–62 (10.3109/13506129509036919)
  66. Evans DA, Funkenstein HH, Albert MS, et al. 1989. Prevalence of Alzheimer’s disease in a community population of older persons. Higher than previously reported.J. Am. Med. Assoc.262:2551– 56 (10.1001/jama.1989.03430180093036)
  67. Glenner GG, Wong CW. 1984. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein.Biochem. Biophys. Res. Commun.120:885– 90 (10.1016/S0006-291X(84)80190-4)
  68. 10.1073/pnas.90.10.4748
  69. Schlossmacher MG, Ostaszewski BL, Hecker LI, et al. 1992. Detection of distinct isoform patterns of the beta-amyloid precursor protein in human platelets and lymphocytes.Neurobiol. Aging13:421– 34 (10.1016/0197-4580(92)90117-G)
  70. 10.1016/0092-8674(95)90073-X
  71. 10.1038/325733a0
  72. Sandbrink R, Masters CL, Beyreuther K. 1996. APP gene family. Alternative splicing generates functionally related isoforms.Ann. NY Acad. Sci.777:281– 87 (10.1111/j.1749-6632.1996.tb34433.x)
  73. 10.1038/19083
  74. Iwatsubo T, Odaka A, Suzuki N, et al. 1994. Visualization of A beta 42(43)positive and A beta 40-positive senile plaques with end-specific A beta-monoclonal antibodies: evidence that an initially deposited A beta species is A beta 1–42(43).Neuron13:45–53 (10.1016/0896-6273(94)90458-8)
  75. 10.1038/360672a0
  76. 10.1038/375754a0
  77. 10.1126/science.7638622
  78. Suzuki N, Cheung TT, Cai XD, et al. 1994. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants.Science264:1336–40 (10.1126/science.8191290)
  79. Armstrong RA. 1994. Differences in beta-amyloid (beta/A4) deposition in human patients with Down’s syndrome and sporadic Alzheimer’s disease.Neurosci. Lett.169:133–36 (10.1016/0304-3940(94)90374-3)
  80. 10.1038/ng0195-21
  81. 10.1111/j.1749-6632.1996.tb34436.x
  82. Blacker D, Tanzi RE. 1998. The genetics of Alzheimer disease: current status and future prospects.Arch. Neurol.55:294– 96 (10.1001/archneur.55.3.294)
  83. 10.1002/ana.410400619
  84. 10.1038/349704a0
  85. Wisniewski T, Frangione B 1992. Molecular biology of Alzheimer’s amyloid–Dutch variant.Mol. Neurobiol.6:75–86 (10.1007/BF02935567)
  86. Mullan M, Crawford F, Axelman K, et al. 1992. A pathogenic mutation for probable Alzheimer’s disease in the APP gene at theN-terminus of beta-amyloid. Nature Genet.1:345–47 (10.1038/ng0892-345)
  87. 10.1126/science.2111584
  88. 10.1126/science.1411576
  89. Tomita T, Maruyama K, Saido TC, et al. 1997. The presenilin-2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue.Proc. Natl. Acad. Sci. USA94:2025–30 (10.1073/pnas.94.5.2025)
  90. 10.1038/19077
  91. 10.1038/34910
  92. Levitan D, Greenwald I. 1995. Facilitation of lin-12-mediated signalling by sel12, aCaenorhabditis elegansS182 Alzheimer’s disease gene.Nature377:351–54 (10.1038/377351a0)
  93. Baumeister R, Leimer U, Zweckbronner I, et al. 1997. Human presenilin 1, but not familial Alzheimer’s disease (FAD) mutants, facilitateCaenorhabditis elegansNotch signaling independently of proteolytic processing.Genes Funct.1:149–59 (10.1046/j.1365-4624.1997.00012.x)
  94. 10.1038/5526
  95. Weidemann A, Paliga K, Durrwang U, et al. 1997. Formation of stable complexes between two Alzheimer’s diseases gene products: presenilin-2 and beta-amyloid precursor protein.Nature Med.3:328–32 (10.1038/nm0397-328)
  96. 10.1038/376775a0
  97. 10.1038/373523a0
  98. 10.1126/science.274.5284.99
  99. 10.1038/nm0198-097
  100. 10.1073/pnas.94.24.13287
  101. 10.1073/pnas.86.15.5810
  102. 10.1038/341162a0
  103. {'key': 'b103', 'first-page': '526', 'volume': '145', 'year': '1994', 'journal-title': 'Am. J. Pathol.'} / Am. J. Pathol. (1994)
  104. 10.1016/S0021-9258(17)31797-0 / J. Biol. Chem. (1994)
  105. Franceschini G. 1996. Apolipoprotein function in health and disease: insights from natural mutations.Eur. J. Clin. Invest.26:733–46 (10.1046/j.1365-2362.1996.2120536.x)
  106. {'key': 'b106', 'first-page': '49', 'volume': '7', 'year': '1989', 'journal-title': 'Dis. Markers'} / Dis. Markers (1989)
  107. 10.1038/ng0194-29
  108. 10.1016/0140-6736(92)93288-X
  109. Gejyo F, Suzuki S, Kimura H, et al. 1997. Increased risk of dialysis-related amyloidosis in patients with the apolipoprotein E4 allele.Amyloid: Int. J. Exp. Clin. Invest.4:13–17 (10.3109/13506129708995263)
  110. 10.1212/WNL.43.8.1467
  111. 10.1038/ng0694-180
  112. 10.1056/NEJM199511093331902
  113. Blacker D, Haines JL, Rodes L, et al. 1997. Apo E-4 and age at onset of Alzheimer’s disease: the NIMH genetics initiative.Neurology48:139–47 (10.1212/WNL.48.1.139)
  114. 10.1002/ana.410380120
  115. Wisniewski T, Castano EM, Golabek AA, et al. 1994. Acceleration of Alzheimer’s fibril formation by apolipoprotein Ein vitro.Am. J. Pathol.145:1030–35
  116. 10.1038/ng1197-263
  117. Maestre G, Ottman R, Stern Y, et al. 1995. Apolipoprotein E and Alzheimer’s disease: ethnic variation in genotypic risks.Ann. Neurol.37:254–59 (10.1002/ana.410370217)
  118. Mayeux R, Saunders AM, Shea S, et al. 1998. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease. Alzheimer’s disease centers consortium in apolipoprotein E and Alzheimer’s disease.N. Engl. J. Med.338:506– 11
  119. 10.1046/j.1471-4159.1997.69051904.x
  120. 10.1038/1243
  121. 10.1073/pnas.95.6.3275
  122. Liao A, Nitsch RM, Greenberg SM, et al. 1998. Genetic association of an alpha 2macroglobulin (Val1000Ile) polymorphism and Alzheimer’s disease.Hum. Mol. Genet.7:1953–56 (10.1093/hmg/7.12.1953)
  123. Castillo GM, Ngo C, Cummings J, et al. 1997. Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer’s disease, accelerates A beta fibril formation, and maintains A beta fibril stability.J. Neurochem.69:2452–65 (10.1046/j.1471-4159.1997.69062452.x)
  124. 10.1126/science.279.5348.242
  125. 10.1159/000137173
  126. {'key': 'b126', 'first-page': '149', 'volume': '87', 'year': '1994', 'journal-title': 'Q.J. Med.'} / Q.J. Med. (1994)
  127. {'key': 'b127', 'first-page': '1186', 'volume': '147', 'year': '1995', 'journal-title': 'Am. J. Pathol.'} / Am. J. Pathol. (1995)
  128. Sorci-Thomas M, Kearns MW, Lee JP, et al. 1993. Apolipoprotein A-I domains involved in lecithin-cholesterol acyltransferase activation. Structure:function relationships.J. Biol. Chem.268:21403–9 (10.1016/S0021-9258(19)36938-8)
  129. 10.1006/bbrc.1997.8005
  130. 10.1016/S0022-2275(20)41439-7 / J. Lipid Res. (1992)
  131. 10.1073/pnas.89.16.7389
  132. {'key': 'b132', 'first-page': '695', 'volume': '88', 'year': '1995', 'journal-title': 'Q.J. Med.'} / Q.J. Med. (1995)
  133. 10.1172/JCI118725
  134. Persey MR, Booth DR, Booth SE, et al. 1998. Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-1.Kidney Int.53:276– 81 (10.1046/j.1523-1755.1998.00770.x)
  135. 10.1006/bbrc.1999.0518
  136. Hamidi Asl L, Liepnicks JJ, Hamidi Asl K, et al. 1999. Hereditary amyloid cardiomyopathy caused by a variant apolipoprotein A1.Am. J. Pathol.154:221– 27 (10.1016/S0002-9440(10)65268-6)
  137. 10.1146/annurev.med.46.1.57
  138. Westermark P, Araki S, Benson MD, et al. 1999. Part 1. Nomenclature of amyloid fibril proteins.Amyloid: Int. J. Exp. Clin. Invest.6:63–66 (10.3109/13506129908993290)
Dates
Type When
Created 23 years, 1 month ago (July 27, 2002, 7:45 a.m.)
Deposited 2 years, 4 months ago (April 23, 2023, 2:59 p.m.)
Indexed 1 month, 1 week ago (July 24, 2025, 7:46 a.m.)
Issued 25 years, 7 months ago (Feb. 1, 2000)
Published 25 years, 7 months ago (Feb. 1, 2000)
Published Print 25 years, 7 months ago (Feb. 1, 2000)
Funders 0

None

@article{Buxbaum_2000, title={The Genetics of the Amyloidoses}, volume={51}, ISSN={1545-326X}, url={http://dx.doi.org/10.1146/annurev.med.51.1.543}, DOI={10.1146/annurev.med.51.1.543}, number={1}, journal={Annual Review of Medicine}, publisher={Annual Reviews}, author={Buxbaum, Joel N. and Tagoe, Clement E.}, year={2000}, month=feb, pages={543–569} }